title: Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy.
authors.affiliation: Department of Dermatology, Centre Hospitalier de Saint-Brieuc, France. Electronic address: gilles.safa@ch-stbrieuc.fr.
authors.forename: Gilles
authors.initials: G
authors.lastname: Safa
authors.affiliation: Department of Dermatology, Centre Hospitalier de Saint-Brieuc, France.
authors.forename: Karine
authors.initials: K
authors.lastname: Luce
authors.affiliation: Department of Dermatology, Centre Hospitalier de Saint-Brieuc, France.
authors.forename: Laure
authors.initials: L
authors.lastname: Darrieux
authors.affiliation: Armor Pathology Laboratory, Plérin, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Tisseau
authors.affiliation: Department of Pathology, Henri Mondor Hospital, Université Paris-Est Créteil, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ortonne
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D016827:CD8 Antigens / Q000276:immunology*; D016572:Cyclosporine / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D000069285:Infliximab; D019310:Pseudolymphoma / Q000139:chemically induced* / Q000188:drug therapy* / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D018570:Risk Assessment; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D016827:CD8 Antigens; D016572:Cyclosporine; D000069285:Infliximab